B Mirror Report:  In the first half of the current fiscal year, leading pharmaceutical manufacturers reported double-digit year-over-year profit growth, bolstered by increased sales and lower input costs in a comparatively stable foreign exchange environment.
During a period when many other businesses battled high operating costs brought on by inflationary pressure, the sector maintained its growth momentum.

Research indicates that “the demand for important pharmaceuticals grew rapidly in the local market whereas large firms were able to handle operating expenses efficiently.”
He pointed out that the need for generic medications, especially those used to treat chronic illnesses, has greatly expanded due to population growth and rising healthcare awareness.
The pharmaceutical industry’s success has been significantly enhanced by the post-pandemic emphasis on medical infrastructure and health readiness.
Research said, “Macroeconomic conditions, including inflation and currency stability, improved during July–December 2025 compared to the same period a year earlier, which also aided profit growth among prominent medication companies.”

Combined earnings of seven top pharmaceutical companies jumped more than 18 per cent year-on-year to Tk 19.34 billion in the July–December period, while total sales rose 16 per cent to Tk 106 billion.

“Higher income levels and greater health awareness have encouraged increased spending on medicines,” Shawon said, adding that rising living standards typically lead to higher consumption of healthcare products.

The Bangladesh Bureau of Statistics reports that during the previous ten years, per capita healthcare spending in Bangladesh almost doubled to $61.9.
Major pharmaceutical companies have been able to sustain robust sales and profit growth thanks to this trend, which is bolstered by decreased financing costs, strong financial situations, and efficient operations.
Square Pharmaceuticals, the country’s largest medicine company, reported a 16 per cent year-on-year growth in earnings in the first half of FY26, driven mainly by greater sales.

Strong domestic demand, export revenue, and contributions from subsidiaries were cited by the corporation as the reasons for the steady growth.

Renata also posted over 25 per cent year-on-year profit growth in the first half of the fiscal year, supported by higher operating profit and reduced finance expenses following a capital restructuring programme.

In its earnings statement, the company said lower raw material costs, access to US dollar funding from the International Finance Corporation (IFC) and reduced foreign exchange volatility helped improve margins.

After completing its restructuring, which included issuing Tk 3.25 billion in preference shares and fully utilizing low-cost IFC funding, Renata claimed a 7.3% decrease in financing expenses.
Its pharmaceutical division, which makes up more than 80% of total revenue, had a 10% gain in revenue, but its animal health division saw no change.
During the first half of FY26, Navana Pharma’s profit increased by 50% year over year thanks to increased sales, better margins, and greater operating cash flows.

The company said efficient production planning, growing market demand and decreased borrowing costs led to the better results.
Among the key companies, IBN Sina Pharma reported the largest profit rise, with a 61% year-over-year increase, backed by

However, pharmaceutical exports climbed only 3 per cent year-on-year to $118 million in July–December 2025, partly due to delayed shipments after export-bound inventory was damaged in a fire at Dhaka airport on October 19, 2025.

Exporters were badly impacted by the fire at Hazrat Shahjalal International Airport’s cargo hamlet, which resulted in damages estimated at around Tk 40 billion.
Alam stated that despite the setback, the industry would be able to accelerate export growth in the upcoming years with ongoing investment, regulatory compliance, and a growing skilled workforce.

The pharmaceutical industry in Bangladesh is predicted to increase by more than 15% during the same period, while the worldwide pharmaceutical market is predicted to rise by 5.8% through 2028, according to Statista.